Antibody-mediated rejection (AMR) is an increasingly recognized form of lung rejection. C4d deposition has been an inconsistent finding in previous reports and its role in the diagnosis has been controversial. We conducted a retrospective single-center study to characterize cases of C4d-negative probable AMR and to compare these to cases of definite (C4d-positive) AMR. We identified 73 cases of AMR: 28 (38%) were C4d-positive and 45 (62%) were C4d-negative. The two groups had a similar clinical presentation, and although more patients in the C4d-positive group had neutrophilic capillaritis (54% vs. 29%, P = .035), there was no significant difference in the presence of other histologic findings. Despite aggressive antibody-depleting therapy, 19 of 73 (26%) patients in the overall cohort died within 30 days, but there was no significant difference in freedom from chronic lung allograft dysfunction (CLAD) or survival between the two groups. We conclude that AMR may cause allograft failure, but that the diagnosis requires a multidisciplinary approach and a high index of suspicion. C4d deposition does not appear to be a necessary criterion for the diagnosis, and although some cases may respond initially to therapy, there is a high incidence of CLAD and poor survival after AMR.
| INTRODUCTION
Lung transplantation is the ultimate treatment for patients with end-stage lung disease, but long-term outcomes remain disappointing. According to the latest International Society for Heart and Lung Transplantation (ISHLT) Registry Report, the median survival after transplantation is approximately 6 years, and the leading cause of death beyond the first year after transplantation is chronic lung allograft dysfunction (CLAD).
1 Antibody-mediated rejection (AMR) is an increasingly recognized form of lung allograft rejection that often results in CLAD development and allograft failure. [2] [3] [4] [5] The ISHLT recently developed a consensus report to establish diagnostic criteria and a working definition of AMR after lung transplantation. 6 These were based on early experience with AMR after kidney and heart transplantation and the conclusions of the national conference to assess AMR in solid organ transplantation. [7] [8] [9] [10] In the ISHLT consensus report on pulmonary AMR, the number of present criteria increases diagnostic certainty, and the diagnosis of definite AMR is based on the presence of allograft dysfunction, histologic evidence suggestive of AMR, compliment component 4d (C4d) deposition, circulating donor-specific antibodies (DSAs), and the reasonable exclusion of other causes. 6 However, the sensitivity of C4d deposition was questioned, and the consensus report recognized that emerging evidence suggests that pulmonary AMR can be diagnosed in the absence of C4d deposition. 6 Indeed, C4d deposition was notably absent in the majority of patients diagnosed with AMR in 2 recent studies. 2, 4 C4d staining has been difficult to interpret in lung biopsies because of poor reproducibility, high background staining, and poor specificity for AMR. [11] [12] [13] Moreover, advances in kidney transplantation have demonstrated that C4d deposition has limited sensitivity in AMR, and C4d-negative AMR is now a widely recognized phenotype. [14] [15] [16] It is notable that this has led to the recognition of a unique AMR pathogenesis independent of complement activation, mediated primarily by natural killer (NK) cell interaction with DSA bound to endothelial cells.
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The purpose of this study was to determine the incidence of C4d-negative probable AMR after lung transplantation and compare the clinical presentation and outcomes to C4d-positive definite AMR.
| METHODS

| Study design and patients
We conducted a retrospective single-center cohort study. Between lung transplant procedures at Barnes-Jewish Hospital; 21 underwent retransplantation. Six recipients were treated with a desensitization regimen before transplantation and were excluded from this study;
an additional patient had a positive virtual crossmatch at the time of transplantation and was also excluded (Figure 1 AMR solely to cases that were C4d-negative and did not include other cases of probable AMR; we did not include cases of probable AMR where DSA was not identified, where there was no abnormal lung pathology, or where other causes of allograft dysfunction could not be excluded. 6 We included cases where bacterial cultures from bronchoscopic specimens were positive if patients had a history of bacterial airway colonization and the clinical picture at the time of presentation was not consistent with bacterial pneumonia. Specifically, we excluded patients who had positive bacterial cultures if they had fever or leukocytosis at presentation. In addition, we excluded cases where a community-acquired respiratory virus, cytomegalovirus (CMV), a mycobacterium, or a fungal pathogen was identified. Our institutional review board approved the study protocol (IRB ID# 201701113).
| Clinical management
At our center, patients and donors undergo low-resolution HLA-A, shown in the online data supplement ( Figure S1 ). A negative C4d stain is illustrated in Figure 2D . A single pathologist (DC) reviewed all cases of definite and probable AMR included in this cohort.
During the study period, recipients were treated with induction immunosuppression consisting of either basiliximab or equine antithymocyte globulin (ATG). Seven recipients who were included in this cohort were enrolled in a multicenter placebo-controlled trial evaluating the efficacy of Fresenius ATG. 20 After transplantation, all recipients were started on maintenance immunosuppression consisting of tacrolimus, prednisone, and either mycophenolate mofetil or azathioprine.
Subsequently, the maintenance regimen was changed for patientspecific indications.
| Statistical analysis
We used descriptive statistics to characterize patients' demographics and compared continuous variables between groups using t-tests (or Wilcoxon-Rank sum tests if the data were not normally distributed).
We compared categorical variables between groups using chi-square tests. Means are expressed ± standard deviation (SD). We used the Kaplan-Meier method to estimate freedom from CLAD, survival, and CLAD-free survival after the onset of AMR, and compared groups using the log rank test. We conducted statistical analysis using SPSS 24.0 (SPSS Inc., Chicago, IL) and Prism 7 (GraphPad Software Inc., La Jolla, CA) and considered P < .05 statistically significant.
| RESULTS
During the study period, 28 recipients (4%) developed C4d-positive definite AMR, and 45 (7%) developed C4d-negative probable AMR; the two groups had similar baseline characteristics (Table 1 ). In all C4d-positive cases, C4d deposition was focal involving <50% of capillaries. Demographics for all patients transplanted during the study period are presented in the online data supplement (Table S1 ). Mean follow-up after the diagnosis of AMR was 2.0 ± 2.8 years. All recipients had a negative virtual crossmatch and a negative direct CDC crossmatch at the time of transplantation. There was no statistically significant difference in the proportion of patients treated with the different induction immunosuppression agents or the different maintenance immunosuppression agents at the time of AMR diagnosis between the two groups (Table 1 ). In the overall cohort, recipients developed AMR a mean 314 ± 464 (median 186) days after transplantation. There was no significant difference in the time of onset of AMR after transplantation between the two groups ( Table 2 ). Patients presented with nonspecific signs and symptoms of acute allograft dysfunction. Fifty-five recipients (75%) were hospitalized, and 28 (38%) required invasive mechanical ventilation. There were no statistically significant differences in the clinical presentation of AMR between the two groups ( Table 2) .
At the time of AMR diagnosis, bacterial cultures from bronchoscopy specimens were positive in 12 patients. There was no statistically significant difference in the proportion of patients who had a cases where a community-acquired respiratory virus, CMV, a mycobacterium, or a fungal pathogen was identified. MFI between the two groups (P = .488). In the overall cohort, acute pneumonitis was the most common histologic finding, occurring in 55 recipients (75%). In addition, concomitant acute cellular rejection (ACR) was present in 19 recipients (26%): 9 had A1, 7 had A2, 3 had A3, and none had A4 (Table 2) . Acute bronchitis and diffuse alveolar damage (DAD) ( Figure 2B ) were identified in 28 (38%) and 25 (34%) recipients, respectively. Finally, neutrophilic capillaritis ( Figure 2A) was present in 28 cases (38%) cases: 15 recipients (54%) in the C4d-positive group and 13 (29%) in the C4d-negative group had capillaritis (Table 2 ; P = .035). Except for capillaritis, there was no significant difference in the distribution of histologic findings between the two groups ( Table 2 ). In addition, there was no significant difference in the distribution of histologic findings between those with C1q-positive DSA and those with C1q-negative DSA (Table S2) .
Our approach to treatment evolved over time, and regimens were individualized based on patients' severity of allograft dysfunction, clinical course, and response to initial therapy. All patients were treated with intravenous immunoglobulin (IVIG). Dosing varied between 500 mg/kg and 2 g/kg, and treatment was continued monthly after the initial dose. The different regimens are listed in Table 3 .
The combination of rituximab and IVIG was the most commonly used regimen (n = 35) ( (Table 3 ). All patients who had concomitant ACR were also treated with methylprednisolone 500 mg daily for 3 days.
There was no significant difference in regimen used between the C4d-positive and the C4d-negative groups ( the C4d-positive and the C4d-negative groups (P = .258). There was no statistically significant association between treatment regimen and DSA clearance (Table S3 ; P = .115). Of the 28 patients who required invasive mechanical ventilation, 10 (36%) were liberated from ventilatory support; there was no statistically significant difference in liberation from ventilatory support between the two groups (P = .172).
In the overall cohort, 19 patients (26%) died within 30 days, but there was no statistically significant difference in 30-day mortality between the two groups; 5 (18%) recipients in the C4d-positive group and 14 (31%) in the C4d-negative group died within 30 days of the diagnosis (P = .210).
Six patients developed CLAD before the diagnosis of AMR and were excluded from the analysis of freedom from CLAD. During the study period, 36 patients in the overall cohort (15 in the C4d-positive group and 21 in the C4d-negative group) developed CLAD after the diagnosis of AMR. There was no significant difference in freedom from CLAD between the C4d-positive and the C4d-negative groups ( Figure 3A) . Among the 36 who developed CLAD, 23 (64%) developed bronchiolitis obliterans syndrome (BOS) and 13 (36%) developed restrictive allograft syndrome (RAS). There was no significant difference in the distribution of CLAD phenotype between the C4d-positive and the C4d-negative groups. In the C4d-positive group, 10 patients developed BOS and 5 developed RAS; similarly, in the C4d-negative group, 13 patients developed BOS and 8 developed RAS (P = .769).
Sixty-one patients (84%) in the overall cohort died (n = 59) or required retransplantation (n = 2); the median allograft survival time after the diagnosis of AMR was 246 days. However, there was no significant difference in allograft survival between the two groups ( Figure 3B ).
CLAD was the leading cause of death, accounting for 30 deaths followed by refractory AMR accounting for 21 deaths, but there was no statistically significant difference in causes of death between the two groups (Table S5 ; P = .950). Similarly, there was no significant difference in CLAD-free allograft survival between the two groups ( Figure 3C ). Although there was no significant difference in freedom from CLAD between those who cleared all DSA and those who had persistent DSA ( Figure 4A) , those who cleared all DSA had significantly better allograft survival ( Figure 4B ) and CLAD-free allograft survival ( Figure 4C ). This difference in allograft survival was due primarily to death from refractory AMR; 21 patients who had persistent DSA died because of AMR compared to none of those who cleared the DSA.
| DISCUSSION
In this study, the incidence of C4d-positive AMR was 4% over a 10-year period. An additional 7% of recipients developed C4d-negative probable AMR for a combined incidence of 11%. Although the ISHLT consensus report classified cases lacking C4d deposition as probable AMR, the working group recognized that "there is building evidence that AMR can be diagnosed confidently in the absence of C4d staining." 6 Indeed, our findings demonstrate that C4d-negative cases have similar clinical presentations and outcomes as C4d-positive cases. This suggests that C4d deposition is not a necessary criterion for the diagnosis of AMR. Interpretation of C4d staining in lung biopsies has been fraught with complications, and C4d deposition has not been a sensitive or specific marker for AMR. 2, 4, [11] [12] [13] In addition, staining of biopsies taken at later stages of AMR after extensive endothelial injury may be patchy or granular and would be interpreted as negative. 21 T A B L E 3 Treatment regimens F I G U R E 3 (A) There was no statistically significant difference in freedom from chronic lung allograft dysfunction (CLAD) between the C4d-positive and the C4d-negative groups (log rank P = .846).
(B) There was no statistically significant difference in allograft survival between the C4d-positive and the C4d-negative groups (log rank P = .581). (C) There was no statistically significant difference in CLAD free allograft survival between the C4d-positive and the C4d-negative groups (log rank P = .771) F I G U R E 4 (A) There was no statistically significant difference in freedom from CLAD between patients who cleared the donorspecific antibody (DSA) and those who had persistent DSA (log rank P = .640). (B) Patients who cleared the DSA had significantly better allograft survival than those who had persistent DSA (log rank P < .0005). (C) Patients who cleared the DSA had significantly better CLAD-free allograft survival than those who had persistent DSA (log rank P = .004) cellular cytotoxicity. 22 However, in contrast to our findings, C4d-positive AMR after kidney transplantation is associated with worse allograft survival than C4d-negative AMR. 23, 24 This raises the suspicion that the lack of C4d deposition in some cases in our cohort is a false negative due to methodological problems with the assay rather than complement-independent pathways. In fact [34] [35] [36] This is consistent with endothelial cells being the focal point of initial alloimmune injury. Neutrophilic capillaritis is an obvious consequence of endothelial cell injury, but this was identified in a minority of cases in the overall cohort. It is important to note that this was seen more frequently in C4d-positive cases than in C4d-negative cases.
Nonetheless, capillaritis is a difficult histologic diagnosis on transbronchial lung biopsies, and it is possible that this was obscured by the findings of acute lung injury or acute pneumonitis in some cases.
As reported previously, there is a high incidence of CLAD and mortality after AMR even among those who have an initial response to therapy.
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This study has multiple limitations. First, because this was a retrospective study, it is possible that we did not identify some cases of AMR. There is currently no widely accepted and standardized definition of acute allograft dysfunction after lung transplantation, and this may have affected our case identification. In addition, our understanding and awareness of AMR evolved during the study period.
Missing cases would affect our reported incidence of AMR. In addition, we excluded cases where the diagnosis was ambiguous because of a concomitant infection. Although this scenario is not uncommon in clinical practice, we sought to identify a cohort of AMR in a stringent manner to avoid misclassifying cases. We did not include other definitions of probable AMR proposed by the ISHLT consensus document in this study because we believe that this is beyond the scope of this study and requires a focused analysis. Another limitation is that we exclusively used immunohistochemistry for the interpretation of C4d deposition. Although immunofluorescence has a better interobserver agreement, 11 our pathology lab is more experienced with staining and interpreting C4d by immunohistochemistry, and this is the clinically used assay at our center. In addition, immunohistochemistry allows C4d staining on specimens submitted in formalin, whereas immunofluorescence requires submission in Michel's solution, which requires making a decision to perform C4d staining at the time of obtaining biopsies rather than having the flexibility to review the morphology first. However, it is possible that discordance between immunohistochemistry and immunofluorescence may be present, and this would result in misclassification of some cases. In addition, we were not able to further characterize DSA by IgG subclass or C1q binding in many cases because of sample availability. Finally, our treatment approach was highly variable and depended on the severity of allograft dysfunction and clinical course. This makes comparing the efficacy of different regimens difficult particularly in light of the small sample size.
We conclude that C4d deposition is not a necessary criterion for the confident diagnosis of AMR in lung transplantation. Furthermore, the most common histologic findings are nonspecific markers of lung injury, and although neutrophilic capillaritis may raise the suspicion of AMR, there are no diagnostic histologic findings. Thus the diagnosis of pulmonary AMR requires a high index of suspicion and a multidisciplinary approach. Moreover, outcomes after AMR remain disappointing despite aggressive immunosuppressive and antibody-directed therapy. Finally, multicenter studies are necessary to validate our findings and identify better therapeutic interventions.
